Brought to you by 
Modex gets rights to Eukarion's skin drug
17 Jun 2014
Executive Summary
Modex Therapeutics (dermatology products) has licensed exclusive worldwide rights to Eukarion's (drugs to treat degenerative and age-related disorders) preclinical ROS (reactive oxygen species) small molecule, designed to prevent and treat radiation-induced skin damage following radiation therapy for cancer patients.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Topical Delivery
-
Drug Delivery
Deal Status
- Final
Deal Type
-
Alliance
- Intra-Biotech Deal
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Modex gets rights to Eukarion's skin drug
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice